Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 5 of 28 for:    sickle cell | "Sickle Cell Trait"

Sickle Cell Hemoglobinopathies and Bone Health

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02306993
Recruitment Status : Recruiting
First Posted : December 3, 2014
Last Update Posted : April 19, 2019
Sponsor:
Information provided by (Responsible Party):
Biree Andemariam, UConn Health

Brief Summary:
This research study has two purposes. The first purpose is to determine whether having sickle cell trait (SCT) is a risk factor for the development of bone thinning at an earlier age than expected. Nearly 10% of African Americans (AA) carry sickle cell trait and most of them are unaware of it. African Americans are less likely to develop thin bones than whites, but if they sustain a bone fracture, they are more likely to die from it. We believe having sickle cell trait may lead to bone thinning and predispose a subset of African Americans to dangerously thin bones. The second purpose is to try to understand why individuals with sickle cell disease (SCD) have thinner bones than healthy individuals do. Doctors have already discovered that people with sickle cell disease have very thin bones, but they have not determined why. Our study will try to identify whether the bone thinning is from the body not making enough bone or from the body losing bone once it is made.

Condition or disease Intervention/treatment
Sickle Cell Disease Sickle Cell Trait Other: Healthy volunteers without SCT Other: Healthy volunteers with SCT Other: Volunteers with SCD

Detailed Description:
SCD is a hereditary disease arising only when two parents carrying sickle cell trait (SCT) conceive a child. SCT is clinically silent but very common in African Americans with a ~10% prevalence, although most carriers are unaware of their status. There are no data on bone mineral density (BMD) or vitamin D status in these individuals. Although it is clear that those with SCD have accelerated bone thinning the effect of SCT on bone metabolism or fractures has not been studied. Although the incidence of hip fracture in AA women is about half that of white women, the etiology and risk factors of fractures in AA women are not clearly defined, and it is intriguing to postulate that SCT may have a relationship to bone metabolism and fracture risk in this population, and thus contribute to racial disparity. We hypothesize that the mechanisms underlying altered bone homeostasis in SCD are different than in the general population but perhaps similar to those with SCT. We also hypothesize that SCT is a state of reduced bone mineralization which may contribute to racially disparate outcomes among AAs with bone fractures. Our objectives are (1) to define the mechanisms of bone loss in SCD and (2) to evaluate parameters of bone metabolism in human subjects with SCT compared to those with normal hemoglobin and those with SCD. We will investigate the effect of SCD and SCT on bone homeostasis in premenopausal AA subjects via serum bone turnover markers, calciotrophic hormones and bone mineral density (BMD) testing. We hypothesize that premenopausal AA women with SCT will have significantly lower BMD and higher serum bone turnover markers than race- and age-matched control AA women. In addition, we will explore Vitamin D status and its relationship to bone turnover and BMD in all three groups. We further postulate that bone homeostasis in SCT subjects will be intermediate between healthy controls and subjects with SCD.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 45 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: Sickle Cell Hemoglobinopathies and Bone Heath
Actual Study Start Date : May 2014
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : December 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Bone Density

Group/Cohort Intervention/treatment
Healthy volunteers without SCT
Includes Healthy African American female volunteer between the ages of 18 and 45 years without sickle cell trait. Their blood and bone density x-ray will help researchers gain a better understanding of what might be different about the way having sickle cell trait affects bone.
Other: Healthy volunteers without SCT
Subjects will undergo bone density evaluation via dual energy x-ray absorptiometry (DEXA) scanning. Subjects will provide a sample of for testing of bone turnover markers, complete blood count, and hemoglobin electrophoresis. Subjects will provide information about their dietary calcium intake and pain burden.

Healthy volunteers with SCT
Includes Healthy African American female volunteer between the ages of 18 and 45 years with sickle cell trait. Their blood and bone density x-ray will help researchers gain a better understanding of what might be different about the way having sickle cell trait affects bone.
Other: Healthy volunteers with SCT
Subjects will undergo bone density evaluation via dual energy x-ray absorptiometry (DEXA) scanning. Subjects will provide a sample of for testing of bone turnover markers, complete blood count, and hemoglobin electrophoresis. Subjects will provide information about their dietary calcium intake and pain burden.

Volunteers with SCD
Healthy African American female volunteer between the ages of 18 and 45 years with sickle cell disease. Their blood and bone density x-ray will help researchers gain a better understanding of what might be different about the way having sickle cell disease affects bone.
Other: Volunteers with SCD
Subjects will undergo bone density evaluation via dual energy x-ray absorptiometry (DEXA) scanning. Subjects will provide a sample of for testing of bone turnover markers, complete blood count, and hemoglobin electrophoresis. Subjects will provide information about their dietary calcium intake and pain burden.




Primary Outcome Measures :
  1. Hemoglobin genotype with serum bone turnover markers and bone density [ Time Frame: 3 years ]
    Assess the association of hemoglobin genotype with serum bone turnover markers and bone density.


Biospecimen Retention:   Samples Without DNA
Blood will be collected once from each subject by certified study staff at UCHC, CCMC or the participating approved community sites in a private setting.Subjects will donate ~12-15 cc of whole blood via venipuncture. Blood will be collected into 3 vacutainer tubes: one 3.5-mL lavender top tube for CBC and hemoglobin electrophoresis, one 3.5-mL yellow top tube for serum calcium and phosphate, and one 5-mL red-top tube for 25-OH vitamin D, P1NP, CTX, and PTH analysis. The


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
The target population includes healthy African American female volunteers with and without SCT and African American female volunteers with SCD.
Criteria

Inclusion Criteria:

  • Age 18-45 years.
  • Female.
  • Regular menstrual periods.
  • Self-identification of African American race.

Exclusion Criteria:

  • Taking oral contraceptives or medications known to influence bone metabolism (e.g. Glucocorticoids, anti-resorptive or anabolic medications for osteoporosis, pharmacologic Vit D dosing).
  • Known metabolic bone disorder (e.g. uncontrolled thyroid disease, hyperparathyroidism).
  • Pregnant, breast-feeding, or within 3 months post-partum.
  • Taking an investigational drug.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02306993


Contacts
Layout table for location contacts
Contact: Quratulain Ali, MPH, CCRP 860-679-7648 qali@uchc.edu

Locations
Layout table for location information
United States, Connecticut
UConn Health Recruiting
Farmington, Connecticut, United States, 06032
Contact: Quratulain Ali, MPH, CCRP    860-679-7648    qali@uchc.edu   
Principal Investigator: Biree Andemariam, M.D         
Sponsors and Collaborators
UConn Health
Investigators
Layout table for investigator information
Principal Investigator: Biree Andemariam, M.D UConn Health

Layout table for additonal information
Responsible Party: Biree Andemariam, Assistant Professor, UConn Health
ClinicalTrials.gov Identifier: NCT02306993     History of Changes
Other Study ID Numbers: 14-136-6
First Posted: December 3, 2014    Key Record Dates
Last Update Posted: April 19, 2019
Last Verified: April 2019
Keywords provided by Biree Andemariam, UConn Health:
Sickle Cell Disease (SCD)
Sickle Cell Trait (SCT)
Additional relevant MeSH terms:
Layout table for MeSH terms
Anemia, Sickle Cell
Hemoglobinopathies
Sickle Cell Trait
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Anemia
Hematologic Diseases
Genetic Diseases, Inborn